Objective: To clarify what the lipidome of biological samples reflects in the pathology of Parkinson’s disease (PD).
Background: The lipid pattern in the cerebrospinal fluid (CSF) is expected to reflect lipids released by the damaged neurons or glial cells or neuroinflammation induced by the imbalance of sphingolipid levels in PD. Therefore, the lipidomics might become a potential biomarker in evaluating the pathogenesis and progression of PD.
Method: We enrolled 33 patients with PD who met the diagnostic criteria of movement disorder society and were admitted to our hospital after May 2020 (19 males, 14 females; age at admission 72.2 ± 7.7 years; disease duration 6.4 ± 3.8 years). Lipidomics in the CSF and plasma collected in the morning fasting was performed with liquid chromatography-tandem mass spectrometry (LC-MS/MS). Among the phospholipids containing fatty acids composed of C14 ~ C22, 50 lipids were measured. Then, their relationship with various clinical scores (ACE-R, MMSE, FAB, MoCA-J, MDS-UPDRS, Geriatric Depression Scale, Epworth Sleepiness Scale, SCOPA-AUT) were analyzed. Next, we investigated their relationship with neurofilament light chain in CSF.
Results: There was no significant relationship between lipidome in CSF and that in plasma in each class of phospholipids. Lipidome in plasma showed no significant correlation with clinical indices. However, the total amount of lysophosphatidylcholine (LPC), phosphatidylethanolamine (PE), and sphingomyelin (SM) in CSF demonstrated a significant negative correlation with MoCA-J and FAB (r > 0.50, p < 0.05). In addition, regarding each lipid in these phospholipids’ classes, 7 of the 8 LPC lipids and all the 7 SM lipids were correlated with MoCA-J. Besides, the amount of Lyso-PC and PC in CSF were significantly related to that of neurofilament light chain.
Conclusion: The CSF lipidomics in PD patients may be useful as a biomarker that predicts cognitive decline and have aspects as a therapeutic target.
To cite this abstract in AMA style:
Y. Mizutani, S. Shima, A. Ueda, M. Ito, H. Watanabe. Close relationship between CSF lipidomic alterations and cognitive decline in Parkinson’s disease. [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/close-relationship-between-csf-lipidomic-alterations-and-cognitive-decline-in-parkinsons-disease/. Accessed June 15, 2025.« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/close-relationship-between-csf-lipidomic-alterations-and-cognitive-decline-in-parkinsons-disease/